Clinical Outcomes Study Using a New Implantable Neurostimulation System for Chronic Intractable Pain

Inclusion Criteria: * Chronic intractable pain of the trunk and/or limbs * Documented history of trunk and/or limb pain of at least 180 days * Overall pain intensity of at least 5 on a 0-10 numerical rating scale (OPI-NRS-11) over the past 180 days based on subject recall * Pass study site's routine psychological/psychiatric evaluation within 180 days before signing the informed consent * Subject is willing and able to comply with all protocol-required follow-up evaluations * 18 years of age or older when written informed consent is obtained * Subject signs informed consent Exclusion Criteria: * Unable to operate the Precision Spectra™ System either by self or with a caregiver * Primary source of pain is cancer-related, pelvic, visceral, anginal or migraine * Overall pain intensity of always 10 on a 0-10 numerical rating scale (OPI-NRS-11) over the past 180 days based on subject recall * Is a high surgical risk * Currently on any anticoagulant medications that cannot be discontinued during perioperative period * Subject requires Magnetic Resonance Imaging (MRI) while implanted with lead(s) and/or the Precision Spectra IPG * Subject is participating (or intends to participate) in another investigational drug or device clinical trial that may influence the data that will be collected for this study * Subjects already implanted with an active implantable device(s) to treat their pain (IPGs, implantable drug pumps, etc) or pacemaker or Implantable Cardiac Defibrillator * Patient is a woman who is pregnant (a urine pregnancy test must be performed within 7 days prior to the stimulation trial procedure in women of child-bearing potential) or nursing or intends to become pregnant during the course of the trial. * Failed to achieve satisfactory relief during the stimulation trial phase